Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 21, 2026

Box Unveils New Controls to Secure AI Agents Operating Across Enterprise Content

View original at finance.yahoo.com
Box Unveils New Controls to Secure AI Agents Operating Across Enterprise Content New capabilities build on Box's security and governance framework, to help enterprises confidently deploy Box-native and third-party AI agents across their content REDWOOD CITY, Calif., July 21, 2026--(BUSINESS WIRE)--Box, Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nomura Research Institute expects Box to provide administrative features needed to safely leverage AI agents, values Box's multi-vendor support for flexibly switching between AI models, and is confident Box's protective layer will keep critical content protected as AI use expands.

    60% confidence
  • 90% of IT leaders identified security, regulatory, and trust concerns as the biggest barrier to granting AI agents access to enterprise content.

    60% confidence
  • 83% of organizations are already experimenting with AI agents across their most critical tasks, and it's critical to create proper security controls so agents function effectively without accessing, modifying, or exposing content beyond their intended task; Box is creating a standard for deploying agents of any kind securely and at scale.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com